GlassScriptPhysician profile
Kari L Cunningham
NPI 1750534657
$53,326.67
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $15K · 2023: $21K · 2024: $5,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,105 · Honoraria: $8,750 · Consulting Fee: $3,973 · Food and Beverage: $2,828 · Travel and Lodging: $1,776 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,105.00 |
| Honoraria | $8,750.00 |
| Consulting Fee | $3,972.50 |
| Food and Beverage | $2,828.34 |
| Travel and Lodging | $1,775.65 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $32,216.12 | 2021-2024 | Xpovio |
| Janssen Biotech, INC. | $17,991.89 | 2021-2024 | Darzalex, Tecvayli, Carvykti |
| Janssen Scientific Affairs, LLC | $936.53 | 2022-2024 | Imbruvica, Talvey, Carvykti |
| Pfizer INC. | $398.21 | 2022-2024 | |
| Incyte Corporation | $298.96 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $189.48 | 2022-2024 | Enhertu |
| Seagen INC. | $154.13 | 2022 | |
| Abbvie INC. | $130.76 | 2022-2024 | |
| Novocure INC. | $124.92 | 2021 | |
| Beigene USA, INC. | $124.89 | 2023 | Brukinsa |
| Genmab U.S., INC. | $111.03 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $82.06 | 2022-2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $72.09 | 2022-2024 | Clonoseq |
| Genzyme Corporation | $64.18 | 2022-2023 | |
| Blueprint Medicines Corporation | $38.96 | 2023-2024 | Ayvakit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.36 | 2022-2024 | Welireg, Keytruda, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $36.97 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.49 | 2022-2023 | Gilotrif |
| Kite Pharma, INC. | $26.79 | 2024 | Yescarta |
| Servier Pharmaceuticals LLC | $24.47 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.07 | 2024 | |
| Exelixis INC. | $18.70 | 2024 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2022 | |
| Kyowa Kirin, INC. | $17.91 | 2024 | Poteligeo |
| Astellas Pharma US INC | $16.56 | 2023 | Xospata |
| Cti Biopharma Corp. | $16.36 | 2023 | Vonjo |
| Celgene Corporation | $16.04 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.01 | 2023 | Imbruvica |
| Genentech USA, INC. | $15.47 | 2024 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $14.58 | 2024 | |
| Pharmacosmos Therapeutics INC. | $14.23 | 2023 | Monoferric |
| Amneal Pharmaceuticals LLC | $13.41 | 2024 | Neulasta, Avastin, Neupogen |
| Eisai INC. | $13.15 | 2024 | |
| Clovis Oncology, INC. | $12.84 | 2022 | |
| Amgen INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.